The case for & against
Bull & Bear analysis
Bearish
Apyx Medical Corporation (NASDAQ: APYX) is an emerging player in the surgical aesthetics and regenerative medicine sectors. The company specializes in innovative technology for body contouring and skin rejuvenation, notably with its AYON Body Contouring System, which is gaining traction in the market. Positioned within the growing theme of minimally invasive surgical procedures, Apyx strives to capture a larger share of the booming demand in aesthetic and cosmetic surgery.
Bull says
- ↑Q2 revenue of $13.9M, up 22% YoY; Surgical Aesthetics sales +28%.
- ↑Gross margin rose to 63.9%; adjusted EBITDA loss shrank to $0.7M.
- ↑AYON system momentum boosted by expanded FDA clearance for liposuction.
- ↑Analysts rate Strong Buy with a $6.6 12-month price target.
- ↑Strong momentum factors and effective leverage management support upside.
- ↑Quality screen indicates potential undervaluation relative to peers.
Bear says
- ↓Earnings yield at -2.5% and weak profitability factors undermine value.
- ↓Book-to-price ratio suggests overvaluation versus tangible assets.
- ↓Negative adjusted EBITDA persists and no dividend yield raises cash risks.
- ↓Shares dipped post-Q2 due to margin outlook concerns.
- ↓Weak growth and dividend factors signal potential operating inefficiencies.
- ↓Low liquidity and small-company status increase downside volatility.
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-08-2026neutral
Transcript signals
Read full transcript analysis ›